SERA PROGNOSTICS, INC. Marketable Securities (Current)
SERA PROGNOSTICS, INC. (SERA) had Marketable Securities (Current) of $42.05 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments
us-gaap:MarketableSecuritiesCurrent · last filed 2026-08-12
- 2026-06-30: Marketable Securities, Current $42.05M.
- 2026-03-31: Marketable Securities, Current $43.23M.
- 2025-12-31: Marketable Securities, Current $35.26M.
- 2025-09-30: Marketable Securities, Current $39.22M.
| Period end | Marketable Securities, Current |
|---|---|
| 2026-06-30 | $42.05M 10-Q · filed 2026-08-12 |
| 2026-03-31 | $43.23M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $35.26M 10-Q · filed 2026-08-12 |
| 2025-09-30 | $39.22M 10-Q · filed 2025-11-13 |
| 2025-06-30 | $35.14M 10-Q · filed 2025-08-06 |
| 2025-03-31 | $40.97M 10-Q · filed 2025-05-07 |
| 2024-12-31 | $42.19M 10-K · filed 2026-03-18 |
| 2024-09-30 | $47.07M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $46.28M 10-Q · filed 2024-08-07 |
| 2024-03-31 | $48.73M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $45.20M 10-K · filed 2025-03-19 |
| 2023-09-30 | $36.46M 10-Q · filed 2023-11-08 |
| 2023-06-30 | $31.54M 10-Q · filed 2023-08-09 |
| 2023-03-31 | $43.59M 10-Q · filed 2023-05-10 |
| 2022-12-31 | $52.83M 10-K · filed 2024-03-20 |
| 2022-09-30 | $49.97M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $53.02M 10-Q · filed 2022-08-10 |
| 2022-03-31 | $43.47M 10-Q · filed 2022-05-10 |
| 2021-12-31 | $46.18M 10-K · filed 2023-03-22 |
| 2021-09-30 | $37.50M 10-Q · filed 2021-11-09 |
| 2020-12-31 | $0.00 10-K · filed 2022-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B | ||
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |